Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Myrexis returns compounds to EpiCept

Sep. 5, 2012

BioLineRx and Biokine Therapeutics enter licensing agreement for hematological cancers

Sep. 5, 2012

Plexxikon discloses novel protein kinase inhibitors

Sep. 5, 2012

Russian group prepares new monoclonal antibodies

Sep. 5, 2012

Roche Glycart patents novel IL-2 immunoconjugates

Sep. 5, 2012

European approval for Pfizer's Inlyta

Sep. 4, 2012

Agios and UPenn establish new collaboration

Sep. 4, 2012

Genentech describes mTOR inhibitor chosen as development candidate

Sep. 4, 2012

Novartis prepares novel c-Met inhibitors

Sep. 4, 2012

U.K. clearance for GenSpera's phase II prostate cancer study

Sep. 4, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...